“Breaking news: Controlled substance compliance failures rock major corporation.”
This is the kind of headline that doesn’t just attract attention. It plants doubt in your whole organization.
Imagine this:
A distributor notices unusual order growth for a controlled substance. It’s flagged, but no one follows up. Six months later, regulators investigate. The distributor is named. What started as a small anomaly has turned into a full-scale compliance failure.
This happens more often than it should. When oversight slips:
- Media coverage builds quickly
- Regulatory investigations gain momentum
- Internal trust begins to unravel
- Revenue and reputation take the hit
Compliance isn’t a checkbox. It’s a daily responsibility and a matter of public safety. Missed patterns can lead to diversion, overdose, and legal exposure. Strong compliance protects both your business and your community.
Built for Compliance. Designed for You.
At Controlled Substance Solutions (CSS™), we create real-time compliance tools to help you reduce risk and meet regulatory standards.
RxDiligence™: Red Flag Detection for Dispensing Data
With RxDiligence™, you can:
- Analyze up to six months of dispensing data per customer
- Apply custom benchmarks to detect potential issues
- Filter by prescriber, geography, drug type, strength, and more
- Compare trends and performance across time or entities
- Make informed compliance decisions using aggregated data insights
- Keep data protected with HIPAA-compliant infrastructure
ARCOS IQ™: Make ARCOS Data Work for You
With ARCOS IQ™, you can:
- Access the latest ARCOS data file on demand
- View summary-level purchases by registrant
- Detect outliers with built-in statistical analysis
- Filter by drug code, strength, registrant type, and geography
- Run custom comparative analyses across one or more pharmacies
Lead with Compliance, Not Damage Control
Most failures are avoidable if you see them coming.
Schedule a demo of RxDiligence™ or ARCOS IQ™ and see how CSS™ helps you catch the issues before they become headlines.